srGAP1 mediates the migration inhibition effect of Slit2-Robo1 in colorectal cancer

Yuyang Feng†, Lei Feng†, Di Yu, Jian Zou* and Zhaohui Huang*

Abstract

Background: The neuronal guidance molecule Slit2 plays a suppressive role in tumorigenesis and progression. We previously showed that Slit2-Robo1 inhibit cell migration in colorectal cancer (CRC). However, little is known about its downstream effectors in CRC. This study tries to identify whether the Slit-Robo Rho GTPase activating protein 1 (srGAP1) could mediate the inhibitory effect of Slit2-Robo1 on CRC cell migration.

Methods: The protein expression of srGAP1 in clinical CRC tissues was tested by immunohistochemistry staining. Conditioned medium was prepared from HEK293 cells stably expressing Slit2-myc, Robo1-HA or Robo1N (a soluble extracellular domain of Robo1). Immunoprecipitation (IP) was applied to check the interaction between Robo1 and srGAP1, and immunofluorescence (IF) was used to observe the subcellular localization of Robo1 and srGAP1. Small GTPase pull-down assay was used to determine the activity of Cdc42. A modified wound healing assay was performed to detect cell migration.

Results: The protein expression of srGAP1 was remarkably decreased in 47.5% of CRC tissues compared with adjacent noncancerous tissues, and the decreased srGAP1 expression was associated with lymphatic invasion, poor tumor differentiation, high TNM stage, and poor survival (P < 0.05). IP and IF assays revealed that srGAP1 was a Robo1-interacting protein and exhibited similar dynamic subcellular distribution after Slit2 treatment in CRC cells. Small GTPase pull-down assay and migration assay indicated that Slit2-Robo1 signaling inhibited Cdc42 activity and CRC cell motility through srGAP1.

Conclusion: Downregulation of srGAP1 in CRC was associated with tumor progression and poor prognosis. srGAP1 is an important downstream molecule of Slit2 signalling in CRC, and mediates the anti-migration function of Slit2 by inhibiting Cdc42.

Keywords: Slit2, Slit-Robo Rho GTPase activating protein 1 (srGAP1), Cell migration, Colorectal cancer

Background

Colorectal cancer (CRC) is one of the most common cancers worldwide [1]. The incidence of CRC persistently increases in China and other developing countries, and CRC remains as an important health concern worldwide [2]. High motility ability of CRC cells is a key factor to prompt tumor metastasis, which is one of the key reasons resulting in therapy failure and cancer-related death.

Tumor progression requires increased cell motility, which is accompanied by increased actin polymerization and enhanced activity of proteins that optimize its turnover. Previous studies have showed that Slit-Robo signaling affects cell motility by controlling the activity of several proteins involved in reorganizing the actin cytoskeleton, including the Rho GTPases family (Rac, Cdc42, and RhoA) [3].

Slits are secreted extracellular matrix proteins expressed in many types of cells and tissues. As the key neuronal guidance molecules, Slits were originally identified to regulate axonal guidance and neuronal migration in the central nervous system by binding to Roundabout receptor family (Robo1-Robo4) [4, 5]. In addition to their functions in nervous system, recent data revealed that...
Slit-Robo pathway also plays key roles in human tumorigenesis and progression [3]. Slit2 is the most common studied member of Slit family and exerts its activity mainly by binding to Robo1. Slit2 is frequently downregulated in many types of cancers and exhibits tumor suppressive functions, especially inhibition of tumor cell migration. Although Zhou et al. [6] reported that Slit2 could prompt CRC tumorigenesis and metastasis, our recent work showed that Slit2 is frequently downregulated in clinical CRC tissues and inhibits CRC cell migration in a Robo-dependent manner [7]. Dallol et al. [8] and Chen et al.[9] also reported the tumor suppressive role of Slit2 in CRC. However, little was known about the detailed regulation mechanism of Slit2-Robo1, especially its downstream targets in CRC.

The Slit-Robo Rho GTPase activating protein 1 (srGAP1) is a key GTPase activating protein (GAP) downstream of Slit-Robo pathway, and has been shown to inhibit neuronal migration [10] and glioma cell invasion [11] by reducing the activation of Cdc42. Whether srGAP1-Cdc42 axis is a key downstream functional target of Slit2 signaling in CRC remains to be elucidated and little was known about the expression and clinical significance of srGAP1 in human cancer.

In this study, we identify that srGAP1 is a key Robo-interacting protein and mediates the migration inhibitory function of Slit2 by inhibiting Cdc42 activity in CRC. Clinical sample analyses revealed that srGAP1 was significantly downregulated in CRC tissues, which was associated with tumor progression and poor patient survival.

Methods

Tumor tissues and cell lines
A total of 156 human primary CRC tissues and their adjacent noncancerous tissues (NCT) were collected with informed consent at Affiliated Hospital of Jiangnan University, and the detailed clinical information of these patients was included in Table 1. This project was approved by the Clinical Research Ethics Committee of the Affiliated Hospital of Jiangnan University.

Human CRC cell lines (HCT8, HCT116, LoVo, Caco2, DLD1, and HT29) and HEK293 cell line were purchased from American Type Culture Collection (ATCC). All of the culture media (Hyclone, USA) were supplemented with 10% fetal bovine serum (FBS) (Clark, Australia). These cells were incubated under the conditions recommended by ATCC.

Antibodies and plasmids
Mouse anti-β-actin (A1978), anti-β-tubulin (T8328) and anti-Flag (F1804) from Sigma-Aldrich (USA); mouse anti-HA (16B12, MMS-101R), anti-myc (9E10, MMS-101R) and rabbit anti-GFP (NB600-308) from Covance Laboratories Ltd (UK); anti-Cdc42 from BD Transduction Laboratories (No.610929, USA); anti-Robo1 from Abcam (ab7279, USA), anti-srGAP1 from Proteintech (13252-1-AP, USA). The plasmid constructs of Robo1-HA, Robo1-myc, Robo1-RFP, RoboN (a soluble extracellular domain of Robo1), srGAP1-Flag, srGAP1-GFP, srGAP1ΔGAP (Δ320–570), GFP-USP33, CACdc42 (constitutively active), DNCdc42 (dominant negative), and GST-PAK1 were generated as described [5, 10, 12]. Plasmid transfection was performed using Lipofectamine 2000 (Invitrogen, USA).

Immunohistochemistry (IHC) staining
Tissue arrays were constructed using 156 paired CRC tissues and NCTs. The protein expression of srGAP1 was measured by IHC method that was performed on 4 μm paraffin-embedded CRC tissue sections. In brief, the slides were hatched with anti-srGAP1 antibody at a dilution of 1:100 overnight at 4 °C, followed by 1 h incubation of secondary antibody. The subsequent steps were performed using GTvision™ III Detection System/ Mo&Rb (DAKO, USA). The protein expression of srGAP1 was scored 0, 1, 2, and 3 according to the percentage and staining intensity of positive colorectal epithelium cells.
Conditioned medium (CM)
HEK293 cells stably expressing Slit2-myc, Robo1-HA or RoboN were established as previously described [5]. To generate CM, these HEK293 stable cells were plated in 10 cm² dishes and grown to approximately 80% confluence in normal growth medium, and were then incubated in 8 mL of DMEM medium supplemented with 5% FBS for 48 h. The supernatant was collected, centrifuged and then stored in −80 °C until use. In some experiments, CM was concentrated using Amicon Ultra centrifugal filtration devices (Millipore, USA), and working concentrations of Slit2 in CM was estimated to be 100 ~ 250 ng/mL according to the silver staining of serial dilutions of CM following SDS-PAGE fractionation.

RNA extraction and RT-PCR
Total RNA was extracted using the RNAiso Plus (Takara, Japan) according to the manufacturer’s instructions. The concentrations of RNA were measured by NanoDrop ND-2000 instrument (NanoDrop, USA) and complementary DNA (cDNA) was synthesized using the HiFiScript cDNA Kit (CWBio, China). RT-PCR was used to detect gene expression in CRC cell lines, with β-actin as an internal control. The primers used were described in our previous study [7].

Western blot and immunoprecipitation (IP)
Western blot was performed as previously described [7], and the dilution ratios for different primary antibodies were 1:3000 (anti-β-actin, anti-β-tubulin, anti-Flag, anti-HA, and anti-myc), 1:2000(anti-GFP), 1:1000(anti-Cdc42, anti-Robo1 and anti-srGAP1). For IP assay, plasmid constructs of Robo1-HA, srGAP1-GFP, srGAP1-Flag, USP33-GFP or control vector were transfected into CRC cells. Forty-eight hours after transfection, cells were lysed using IP lysis buffer (1% Triton-100, 10% Glycerol, and 1 mM EDTA in TBS buffer), and IP was performed using anti-HA or anti-Flag as described previously [5].

Immunofluorescence (IF)
CRC cells were cotransfected with plasmids of Robo1-RFP, srGAP1-GFP or control. Forty-eight hours after transfection, cells were treated with mock or Slit2 CM for 10 min and were then fixed with 4% paraformaldehyde at room temperature for 30 min. The images were obtained with an inverted fluorescence microscope (Olympus, Japan).

Small GTPase pull-down assay
GST-PAK1 fusion protein was expressed in E. coli (BL21 strain), and purified by glutathione-sepharose affinity chromatography. Purified GST-PAK1 protein was incubated with GST-sepharose beads and used for GST pull-down assay to detect the GTP-loading of Cdc42 (GTP-Cdc42).

To study the potential regulation of Slit2 on Cdc42 activity in CRC, different plasmids were transfected into CRC cells. Forty-eight hours after transfection, cells were lysed in ice-cold IP lysis buffer and were subjected to GST pull-down assay. Briefly, total cell lysates were incubated with GST-sepharose beads loaded with GST-PAK1 protein at 4 °C for 2 h. The beads were washed three times with lysis buffer. Bounded proteins were eluted by incubation in sample buffer at 95 °C for 10 min and separated by 15% polyacrylamide gel electrophoresis. Bounded Cdc42 was analyzed by Western blot using an anti-Cdc42 antibody.

Cell migration assay
A modified wound healing assay was performed to detect cell migration as we described previously [7]. Briefly, photo-etched grid coverslips (Bellco Biotechnology, USA) were coated with 10 μg/mL poly-L-lysine, and cells were then seeded on the coated coverslips and grown to confluence in the 3.5 cm dish. A wound scratch was made by scraping a micropipette tip across the cell monolayer. After removing the dislodged cells by gentle washing with culture media, cells were treated with CM for 10 h. At 0 h and 10 h after wound formation, phase-contrast images of the wound-healing process were photographed under an inverted microscope. Ten representative images were taken at the corresponding positions marked by letters on the etched grid coverslips, and the directional cell migration was measured as the forward distance that individual cells migrated from the wound edge line at the zero time point.

Statistical analysis
The results are presented as the mean values ± SEM. The data were subjected to χ² test, Student’s t-test, the Mann–Whitney U test or the Spearman Rank correlation test. Kaplan-Meier survival analyses and the log-rank test were carried out to determine differences in overall survival (OS). The Cox proportional hazards model was used to estimate hazard ratios (HRs) and their 95% confidence intervals (CIs), representing the overall relative risk of death. A P value of less than 0.05 was considered statistically significant. The Graphpad prism 5.0 software (GraphPad Software, USA) and SPSS 20.0 package (IBM, USA) were used for the statistical analyses and scientific graphing, respectively.

Results
srGAP1 is downregulated in CRC and is associated with poor survival
Little was known about the expression and clinical significance of srGAP1 in human cancers, including CRC, so we measured the protein levels of srGAP1 in 156 paired CRC and NCT tissues by IHC staining. The
srGAP1 expression results were not available in 34 NCT samples due to technical difficulty in the tissue microarray construction and IHC staining. As shown in Fig. 1a, srGAP1 was expressed mainly in cytoplasm and was significantly downregulated in 47.5% (58 of 122) of CRCs compared with NCTs (Fig. 1b). To evaluate the clinical significance of srGAP1 in CRC, the potential relationships between srGAP1 expression and patients’ clinicopathological characteristics were analyzed (Table 1). Noticeably, srGAP1 expression in CRCs was significantly correlated with tumor differentiation (Spearman $r = -0.162$, $P = 0.044$), lymphatic invasion (Spearman $r = -0.194$, $P = 0.015$) and TNM stage (Spearman $r = -0.202$, $P = 0.011$), suggesting that srGAP1 expression was associated with tumor progression.

Survival analysis showed that patients with low srGAP1 expression (score 0 or 1) had a significantly poorer OS than patients with high srGAP1 expression (score 2 or 3) ($\chi^2 = 7.815$, $P = 0.005$, Fig. 1c). Univariate analysis on these 156 CRCs showed that relative low srGAP1 expression, positive nodal status, poor differentiation and higher TNM stage were correlated with decreased survival time (Table 2). The four parameters were then subjected to a Cox multivariate analysis. After adjusting for nodal status, tumor differentiation and TNM stage, multivariate analyses revealed that patients with high srGAP1 expression show a trend of prolonged survival time as compared to patients with low srGAP1 expression (HR = 0.613; 95% CI, 0.360–1.041, $P = 0.070$) (Table 2). Collectively, these data suggest the tumor suppressive role of srGAP1 in CRC.

**Slit2, Robo1 and srGAP1 expression in CRC cell lines**

The mRNA levels of Slit2, Robo1 and srGAP1 were detected in CRC cell lines using RT-PCR. The results revealed that both Slit2 and Robo1 were expressed in HT29 and LoVo cells, whereas srGAP1 mRNA expressed in all these six CRC cell lines with lowest expression in HT29 cells (Fig. 2a). Western blot results confirmed the Robo1 expression in HT29 and LoVo cells, whereas no detectable srGAP1 protein was observed in HT29 cells (Fig. 2b). Based on these results, we focused on LoVo cell line for the subsequent experiments. Since no satisfactory anti-Slit2 antibody could be used to detect the endogenous Slit2 protein expression based on our preliminary study, the anti-myc antibody was used to detect the secretory Slit2 protein in the CM from HEK293 cells stably expressing Slit2-myc (Fig. 2c).

To investigate potential role of srGAP1 in CRC, we analyzed its alteration frequency in CRC using an online database tool (http://www.cbioportal.org/public-portal/index.do). Based on the data from 3 different CRC
cohorts, srGAP1 locus was found to be mutated in 4% ~ 7% CRCs (Fig. 1d), whereas no deletion or amplification was observed.

**srGAP1 is a Robo1-interacting protein in CRC**

Previous studies have revealed that srGAP1 could interact with Robo1 in neuron [10, 12]. To check potential interaction between Robo1 and srGAP1 in CRC cells, we performed CoIP assay. Plasmids of Robo1-HA, srGAP1-GFP or empty vector were transfected into LoVo cells. After IP using an anti-HA antibody, srGAP1 was detected in the immunoprecipitates of the cells expressing both Robo1-HA and srGAP1-GFP proteins, but not that of the control cells (Fig. 3a). To further confirm it, we performed CoIP using an anti-Flag antibody in LoVo and HCT116 cells cotransfected with Robo1-HA, srGAP1-Flag and/or USP33-GFP (also a Robo1-interacting protein). CoIP results showed that Robo1 and USP33 could be detected in the immunoprecipitates of LoVo cells expressing endogenous Robo1 but not in those of HCT116 cells without endogenous Robo1 expression (Fig. 3b). These results confirmed that Robo1 could interact with srGAP1 and USP33 in CRC cells, and srGAP1 could not interact with USP33 directly.

To check whether srGAP1 show similar subcellular localization as Robo1 in CRC cells, we performed immunofluorescence assay by cotransfecting Robo1-RFP and srGAP1-GFP plasmids into LoVo cells. As shown in Fig. 3c, most of Robo1-RFP and srGAP1-GFP were distributed in the perinuclear compartment, and only a low ratio of fluorescence (RFP or GFP) was observed at the plasma membrane in the Mock-treated cells. Whereas the fluorescence signals become stronger at the plasma membrane after Slit2 treatment, suggesting that Slit2 could initiate the redistribution of Robo1 and srGAP1 to

---

### Table 2 Univariate and multivariate analyses of OS for the 156 CRC patients

|                        | Univariate analysis | Multivariate analysis |
|------------------------|---------------------|-----------------------|
|                        | \( P \)  | HR  | 95% CI   | \( P \)  | HR  | 95% CI   |
| Ages (<64 / ≥64)       | 0.071  | 1.567 | 0.962–2.551 |            |      |        |
| Gender (male/female)   | 0.404  | 0.815 | 0.505–1.317 |            |      |        |
| Tumor size (<5 cm / ≥25 cm) | 0.817  | 0.945  | 0.585–1.527 |            |      |        |
| Nodal status (negative/positive) | 0.000  | 2.823  | 1.689–4.719 | 0.050  | 0.299  | 0.089–1.002 |
| Differentiation (well or moderately/poorly) | 0.000  | 3.358  | 2.004–5.625 | 0.002  | 2.442  | 1.393–4.281 |
| Tumor stage (I + II/ III + IV) | 0.000  | 3.342  | 1.956–5.711 | 0.001  | 7.529  | 2.167–26.156 |
| srGAP1 expression (low/ high) | 0.006  | 0.487  | 0.290–0.817 | 0.070  | 0.613  | 0.360–1.041 |

HR hazard ration, 95%, CI 95% confidence interval

---

**Fig. 2** Slit2 inhibits CRC cell migration in a Robo dependent manner. a The mRNA expression of components in the Slit/Robo signaling in CRC cell lines. b The protein expressions of Robo1 and srGAP1 in CRC cell lines were detected by western blot, with beta-actin as a loading control. c Detection of Slit2-myc in slit2 conditional medium (CM). d Mutation at srGAP1 locus was analyzed based on data obtained from the Stand Up to Cancer cBio portal (http://cbio.mskcc.org/su2c-portal/)
the plasma membrane, which is consistent with our previous report [7]. Collectively, IF results show that srGAP1 and Robo1 have similar subcellular localization in the Slit2-treated CRC cells.

**Slit2-Robo1 inhibits Cdc42 activity through srGAP1**

Cdc42, a key member of Rho GTPases, could prompt cell migration by regulating actin cytoskeleton. Previous work revealed that Slit2 could increase srGAP1-Robo1 interaction and inactivate Cdc42, resulting in decreased cell motility in neuronal system [10]. So we checked the GTPase activity of Cdc42 in LoVo cells transfected with Slit2, RoboN, srGAP1-GFP, or srGAP1ΔGAP using GST pull-down assay (Fig. 4a). The results showed that the ectopic expression of Slit2 decrease the levels of Cdc42-GTP, which could be blocked by RoboN, suggesting that the effect is mediated by Robo (Fig. 4b). Similar results were obtained by treatment with Slit2 and RoboN CM (data not shown).

We then checked the role of srGAP1 in the regulation of Cdc42 by Slit2-Robo1 signaling. As shown in Fig. 4c, overexpression of srGAP1 could enhance the inhibitory effect of Slit2 on Cdc42 activity, whereas inhibiting of srGAP1 could block Slit2-mediated inactivation of Cdc42. Taken together, these results demonstrate that Slit2-Robo1 signaling inhibits Cdc42 activity through srGAP1.

**srGAP1 mediates the migration inhibition function of Slit2 by inactivating Cdc42 activity in CRC**

Our previous work reveals that Slit2 inhibits CRC cell migration in a Robo-dependent manner [7]. To check whether the inhibitory effect of Slit2 is mediated by srGAP1 in CRC, plasmids of srGAP1 or its dominant negative mutant (srGAP1ΔGAP) were transfected into LoVo cells. Migration assay showed that ectopic srGAP1 expression significantly enhanced the migration inhibition effect of Slit2, whereas srGAP1ΔGAP blocked it (Fig. 5a-b) in LoVo cells. In addition, similar results were observed in a Transwell assay (data not shown). Collectively, these data suggest that srGAP1 is a key downstream effector of Slit2-Robo1 signaling.

Further study showed that blocking Cdc42 activity using a dominant negative form of Cdc42 (DNCdc42) could
mimic the migration inhibition effect of Slit2, whereas ectopic expression of CACdc42 (constitutively active) could retrieve the decreased cell motility in Slit2-treated CRC cells, suggesting that Cdc42 is a major functional target of Slit2-Robo1-srGAP1 signaling in inhibiting CRC cell migration (Fig. 5c-d).

Discussion

Slit-Robo signaling plays extensive role in a variety of tissue types besides theirs key role in nervous system [3, 13]. We previously revealed that Slit2 is downregulated in CRC and inhibits CRC cell migration [7]. In this study, we revealed that srGAP1 is significantly downregulated in CRC tissues, and was associated with tumor progression and survival. Further functional and mechanic analyses identified that srGAP1 mediates the migration inhibition function of Slit2 by suppressing Cdc42 activity in CRC.

Slits are important modulators of cell migration both in neuronal and non-neuronal cells. Previous studies have showed that Slit2-Robo1 pathway was frequently inactivated in human cancers, including CRC [7, 8]. Several downstream effectors, including Abl [14], Dock [15], Ena (32), ERK1/2 [16], small Rho GTPases [10], USP33 [7] and Vilse [17], have been reported to mediate the inhibitory effect of Slit2-Robo1 signaling on cell motility, proliferation, apoptosis and angiogenesis in different cell types.

A role for Rho GTPase-activating proteins in repulsion mediated by Robo has been shown in neuronal migration [10] and glioma cell invasion [11]. Small GTPases of the Rho family, including RhoA, Rac1 and Cdc42, are key regulators of actin cytoskeletal dynamics in mammals [18, 19]. These GTPases switch between an inactive status (GDP-bound) and an active status (GTP-bound), and guanine nucleotide exchange factors activate Rho GTPases while GAPs inactivate them. The binding of Slit2 modifies the cytoplasmic domains of the Robo1, and prompts the recruitment of srGAP1 to the intracellular domain of Robo1 and the inactivation of Cdc42 in neuron, suggesting srGAP1-Cdc42 a key regulatory axis of Slit2-Robo1 signaling in neuronal migration [10]. In this study, we confirmed that srGAP1 binds to Robo1 in responding to the Slit2 treatment and mediates its tumor suppressive function in CRC. Interestingly, a recent study reported srGAP1 as a candidate susceptibility gene in papillary thyroid carcinoma [20], and several mutations of srGAP1 identified in papillary thyroid carcinoma resulted in severely impaired ability of srGAP1 to inactivate CDC42. Our analysis also observed srGAP1

Several downstream effectors, including Abl [14], Dock [15], Ena (32), ERK1/2 [16], small Rho GTPases [10], USP33 [7] and Vilse [17], have been reported to mediate the inhibitory effect of Slit2-Robo1 signaling on cell motility, proliferation, apoptosis and angiogenesis in different cell types.

A role for Rho GTPase-activating proteins in repulsion mediated by Robo has been shown in neuronal migration [10] and glioma cell invasion [11]. Small GTPases of the Rho family, including RhoA, Rac1 and Cdc42, are key regulators of actin cytoskeletal dynamics in mammals [18, 19]. These GTPases switch between an inactive status (GDP-bound) and an active status (GTP-bound), and guanine nucleotide exchange factors activate Rho GTPases while GAPs inactivate them. The binding of Slit2 modifies the cytoplasmic domains of the Robo1, and prompts the recruitment of srGAP1 to the intracellular domain of Robo1 and the inactivation of Cdc42 in neuron, suggesting srGAP1-Cdc42 a key regulatory axis of Slit2-Robo1 signaling in neuronal migration [10]. In this study, we confirmed that srGAP1 binds to Robo1 in responding to the Slit2 treatment and mediates its tumor suppressive function in CRC. Interestingly, a recent study reported srGAP1 as a candidate susceptibility gene in papillary thyroid carcinoma [20], and several mutations of srGAP1 identified in papillary thyroid carcinoma resulted in severely impaired ability of srGAP1 to inactivate CDC42. Our analysis also observed srGAP1

Several downstream effectors, including Abl [14], Dock [15], Ena (32), ERK1/2 [16], small Rho GTPases [10], USP33 [7] and Vilse [17], have been reported to mediate the inhibitory effect of Slit2-Robo1 signaling on cell motility, proliferation, apoptosis and angiogenesis in different cell types.

A role for Rho GTPase-activating proteins in repulsion mediated by Robo has been shown in neuronal migration [10] and glioma cell invasion [11]. Small GTPases of the Rho family, including RhoA, Rac1 and Cdc42, are key regulators of actin cytoskeletal dynamics in mammals [18, 19]. These GTPases switch between an inactive status (GDP-bound) and an active status (GTP-bound), and guanine nucleotide exchange factors activate Rho GTPases while GAPs inactivate them. The binding of Slit2 modifies the cytoplasmic domains of the Robo1, and prompts the recruitment of srGAP1 to the intracellular domain of Robo1 and the inactivation of Cdc42 in neuron, suggesting srGAP1-Cdc42 a key regulatory axis of Slit2-Robo1 signaling in neuronal migration [10]. In this study, we confirmed that srGAP1 binds to Robo1 in responding to the Slit2 treatment and mediates its tumor suppressive function in CRC. Interestingly, a recent study reported srGAP1 as a candidate susceptibility gene in papillary thyroid carcinoma [20], and several mutations of srGAP1 identified in papillary thyroid carcinoma resulted in severely impaired ability of srGAP1 to inactivate CDC42. Our analysis also observed srGAP1
mutations in a fraction of CRC tumors and suggested potential roles of srGAP1 in CRC tumorigenesis, which deserves further investigations.

Due to the key regulatory role of Cdc42 in actin cytoskeletal dynamics, many studies have demonstrated its importance in mediating tumor aggression, and propose it a promising target of cancer therapy [21]. That CDC42 prompts cell motility has been reported in many types of human cancers [11, 19, 22–30], especially in CRC [31–34]. In this study, we revealed that Slit2 inhibited CRC cell migration via repressing Cdc42 activity. When Robo1 or srGAP1 activity was blocked, the Cdc42 activity was rescued in Slit2-treated CRC cells. At the same time, blocking Cdc42 activity could mimic the inhibitory effect of Slit2 on CRC migration, whereas ectopic expression of CACdc42 (constitutively active) retrieved the decreased cell motility by Slit2 treatment. *P < 0.001; **P < 0.0001

Fig. 5 srGAP1 mediates the migration inhibitory function of Slit2 by inhibiting Cdc42 activity in CRC cells. a-b Slit2 inhibits CRC motility through srGAP1. Ectopic expression of srGAP1 enhanced the inhibitory effect of Slit2 on the migration of LoVo cells, whereas blocking the srGAP1 activity by srGAP1ΔGAP rescued the migration ability of Slit-treated LoVo cells. c-d Cdc42 is a major functional target of the Slit2-Robo1 signaling in inhibiting CRC cell migration. Blocking Cdc42 activity using DNCdc42 (dominant negative) mimicked the inhibitory effect of Slit2 on the CRC cell migration, whereas ectopic expression of CACdc42 (constitutively active) retrieved the decreased cell motility by Slit2 treatment.

*P < 0.001; **P < 0.0001
migration also had been reported [11, 29], suggesting Cdc42 a common key target of the Slit2-Robo1 signaling in human cancers. Based on these data and our previous study [35], we propose a working model for the Slit2-Robo1 signaling transduction pathway in CRC cells (Fig. 6).

Although srGAP1 plays an important role in tumor progression, little was known about its expression and clinical significance in human cancers, including CRC. Our data showed, for the first time, that srGAP1 expression was significantly downregulated in CRC tissues. Decreased expression of srGAP1 in CRC tissues was associated with several key features of tumor aggression and progression, including lymphatic invasion, tumor differentiation and TNM stage. Furthermore, srGAP1 was identified as a potential predictor for patient survival. These data were in concordance with its role in mediating the inhibitory function of Slit2 signaling on the CRC cell motility and metastasis [7].

Conclusion
In summary, our data revealed that the downregulation of srGAP1 in CRC tissues is associated with tumor progression and poor prognosis, and srGAP1-Cdc42 regulatory axis is a key downstream target of Slit2-Robo1 pathway in CRC. Slit2-Robo1-srGAP1-Cdc42 pathway appears to be a promising treatment target for CRC, and deserves further investigations.

Abbreviations
CI: Confidence interval; CM: Conditioned medium; CRC: Colorectal cancer; FBS: Fetal bovine serum; HR: Hazard ratio; IF: Immunofluorescence; IHC: Immunohistochemistry; IP: Immunoprecipitation; NCT: Adjacent noncancerous tissue; OS: Overall survival; srGAP1: The Slit-Robo Rho GTPase activating protein 1

Acknowledgments
We thank Jane Y. Wu (Northwestern University Feinberg School of Medicine, Chicago, USA) for providing the plasmids of Slit-Robo pathway mentioned in the paper.

Funding
This work was partially supported by grants from National Natural Science Foundation of China (81000867, 81272299 and 81672328 for ZH, 81372710 for ZJ), Natural Science Foundation of Jiangsu Province (BK20150004) (ZH), the Fundamental Research Funds for the Central Universities (NOJUSRP51619B) (ZH), Medical Key Professionals Program of Jiangsu Province (RC2011031) (ZH), “333” Talents Project of Jiangsu Province, and Hospital Management Center of Wuxi (YGZXM1401) (ZH).

Availability of data and materials
Data sharing is applicable to this article.

Authors’ contributions
ZH and JZ conceived and designed the experiments. ZH, YF and LF performed the experiments. LF coordinated the research and analysed the data. ZH and LF wrote the manuscript. DY supported the experiments. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.
Ethics approval and consent to participate
This project was approved by the Clinical Research Ethics Committee of the Affiliated Hospital of Jiangnan University, and all tumor tissues were collected with informed consent at Affiliated Hospital of Jiangnan University by scanned ethical approval has been attached.

Author details
1Wuxi Oncology Institute, Affiliated Hospital of Jiangnan University, 200 Hui He Road, Wuxi, Jiangsu 214062, China. 2Wuxi Medical School, Jiangnan University, Wuxi, Jiangsu 214122, China. 3Department of Clinical Laboratory Science, Wuxi People’s Hospital of Nanjing Medical University, 299 Qingyang Road, Wuxi, Jiangsu 214023, China.

Received: 28 August 2016 Accepted: 9 October 2016

Published online: 07 December 2016

References
1. Segel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
2. Chen W, Zheng R, Baade PD, Zeng S, Zhang H, Bray F, Jemal A, Yu QX, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.
3. Ballard MS, Hinck L. A roundabout way to cancer. Adv Cancer Res. 2012;114:187–235.
4. Wu W, Wong K, Chen J, Jiang Z, Dupuis S, Wu JY, Rao Y. Directional guidance of neuronal migration in the olfactory system by the protein Slit. Nature. 1999;400:802–6.
5. Li HS, Chen JH, Wu W, Fatyal T, Zhou L, Yuan W, Dupuis S, Jiang ZH, Nash W, Gick C, et al. Vertebrate slit, a secreted ligand for the transmembrane protein roundabout, is a repellent for olfactory bulb axons. Cell. 1999;96:807–18.
6. Zhong WJ, Geng ZH, Chi S, Zhang W, Niu XF, Lan SJ, Ma L, Yang X, Wang LJ, Ding YQ, et al. slit-robosignaling induces malignant transformation through Hakai-mediated E-cadherin degradation during colorectal epithelial cell carcinogenesis. Cell Res. 2011;21:609–26.
7. Huang Z, Wen P, Kong R, Cheng H, Zhang B, Quan C, Bian Z, Chen M, Zhang Z, Chen X, et al. USP33 mediates Slit-Robo signaling in inhibiting colorectal cancer cell migration. Int J Cancer. 2015;136:1792–802.
8. Dallof A, Morton D, Maher ER, Latif F. Slit2 axon guidance molecule is frequently inactivated in colorectal cancer and suppresses growth of colorectal carcinoma cells. Cancer Res. 2003;63:1054–8.
9. Chen WF, Gao WD, Li QL, Zhou PH, Xu MD, Yao LQ. SLIT2 inhibits cell migration in colorectal cancer through the AKT-GSK3beta signaling pathway. Int J Colorectal Dis. 2013;28:933–40.
10. Wong K, Ren XR, Huang YZ, Xie Y, Liu G, Sato H, Tang H, Wen L, Brady-Kalnay SM, Mei L, et al. Signal transduction in neuronal migration: roles of GTPase-activating proteins and the small GTPase Cdc42 in the Slit-Robo pathway. Cell. 2001;107:209–21.
11. Yim JJ, Hu B, Jarzylnka MJ, Feng H, Liu KW, Wu JY, Ma HI, Cheng SY. Slit2 inhibits glioma cell invasion in the brain by suppression of Cdc42 activity. Neuro Oncol. 2009;11:779–89.
12. Yuasa-Kawada J, Kinoshita-Kawada M, Wu G, Rao Y, Wu JY. Midline crossing and Slit responsiveness of commissural axons require USP33. Nat Neurosci. 2009;12:1087–9.
13. Dallof A, Da Silva NF, Aicava P, Minna JD, Bieche I, Maher ER, Latif F, Slit2, a human homologue of the Drosophila Shh gene, has tumour suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res. 2002;62:5874–80.
14. Bashaw GJ, Kidd T, Murray D, Dawson T, Goodman CS. Repulsive axon guidance: Abelson and Enabled play opposing roles downstream of the roundabout receptor. Cell. 2000;101:703–15.
15. Fan X, Labrador JP, Hing H, Bashaw GJ. Slit stimulation recruits Dock and Pak to the roundabout receptor and increases Rac activity to regulate axon repulsion at the CNS midline. Neuron. 2003;40:113–27.
16. Wu JY, Feng L, Park HT, Havioglu N, Wen L, Tang H, Bacon KB, Jiang Z, Zhang X, Rao Y. The neuronal repellent Slit inhibits leukocyte chemotaxis induced by chemotactic factors. Nature. 2001;410:948–52.
17. Lundstrom A, Gallo M, Englund C, Steneberg P, Hemphala J, Aspenstrom P, Kelemen K, Falilieeva L, Dickson BJ, Samnakovils C, Vilse, a conserved Rac/Cdc42 GAP mediating robo repulsion in tracheal cells and axons. Genes Dev. 2004;18:2161–71.
18. Liu XP, Wang HB, Yang K, Sui AH, Shi Q, Qu S. Inhibitory effects of adenovirus mediated tandem expression of RhoA and RhoC shRNAs in HCT116 cells. J Exp Clin Cancer Res. 2009;28:52.
19. Chander H, Trusdell P, Meens J, Craig AW. Transducer of Cdc42-dependent actin assembly promotes breast cancer invasion and metastasis. Oncogene. 2013;32:3080–90.
20. He H, Bronisz A, Lyanaranachchi S, Nagy R, Li Wu, Huang Y, Akagi K, Saji M, Kula D, Wojcicka A, et al. SRFAP1 is a candidate gene for papillary thyroid carcinoma susceptibility. J Clin Endocrinol Metab. 2013;98:E973–80.
21. Arias-Romero LE, Chernoff J. Targeting Cdc42 in cancer. Expert Opin Ther Targets. 2013;17:263–73.
22. Jain M, Bhat GP, Vijayraghavan K, Inamdar MS. Rudhira/BCAS3 is a cytoskeletal protein that controls Cdc42 activation and directional cell migration during angiogenesis. Exp Cell Res. 2012;318:753–67.
23. Mythreye K, Bloge GC. The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42. Proc Natl Acad Sci U S A. 2009;106:2211–6.
24. Reymond N, Im JH, Gaig R, Vega FM, Borda d, Water, Garcia-Franco J, Perez-Palacios R, Espina C, Valderrama F, Muschel RJ, Ridley AJ. Cdc42 promotes transendothelial migration of cancer cells through beta1 integrin. J Cell Biol. 2012;199:653–68.
25. Guo J, Yu X, Gu J, Lin Z, Zhao G, Xu F, Lu C, Ge D. Regulation of CXCR4/AKT-signaling-induced cell invasion and tumor metastasis by RhoA, Rac-1, and Cdc42 in human esophageal cancer. Tumour Biol. 2016;37:6371–8.
26. Du DS, Yang XZ, Wang Q, Dai W, Kui WX, Liu YL, Chu D, Tang XJ. Effects of Cdc42 on the proliferation and invasion of gastric cancer cells. Mol Med Rep. 2016;13:550–4.
27. Ye H, Zhang Y, Geng L, Li Z. Cdc42 expression in cancer tissue and its effects on cervical tumor invasion and migration. Int J Oncol. 2015;46:757–63.
28. Yang T, Chen T, Li Y, Gao L, Zhang S, Wang T, Chen M. Downregulation of miR-25 modulates non-small cell lung cancer cells by targeting Cdc42. Tumour Biol. 2015;36:1903–11.
29. Tseng RC, Chang JM, Chen JH, Huang WR, Tang YS, Kuo JY, Yen JJ, Lai WW, Wang YC. Deregulation of SLIT2-mediated Cdc42 activity is associated with esophageal cancer metastasis and poor prognosis. J Thorac Oncol. 2015;10:189–98.
30. Chang JS, Su CY, Yu WH, Lee JH, Wu JY, Tai KC, Jan YH, Yang YF, Shen CN, Shew JY, et al. GIT1 promotes lung cancer cell metastasis through modulating Rac1/Cdc42 activity and is associated with poor prognosis. Oncotarget. 2015;6:36278–91.
31. Gomez Del Pulgar T, Valdes-Mora F, Bandes E, Perez-Palacios R, Espina C, Cejas P, Garcia-Cabezas MA, Nistal M, Casado E, Gonzalez-Baron M, et al. Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism. Int J Oncol. 2008;33:185–93.
32. Ke TW, Hsu HL, Wu YH, Chen WT, Cheng YW, Cheng CW. MicroRNA-224 suppresses colorectal cancer cell migration by targeting Cdc42. Dis Markers. 2014;2014:617150.
33. Liu M, Lang N, Qiu M, Xu F, Li Q, Tang Q, Chen J, Chen X, Zhang S, Liu Z, et al. miR-137 targets Cdc42 expression, induces cell cycle G1 arrest and inhibits invasion in colorectal cancer cells. Int J Cancer. 2011;128:769–79.
34. Xiao B, Chen D, Luo S, Hao W, Jiang F, Liu T, Wang S, Geng Y, Li L, Xu W, et al. Extracellular translationally controlled tumor protein promotes colorectal cancer invasion and metastasis through Cdc42/JNK/MMP9 signaling. Oncotarget. 2016; doi: 10.18632/oncotarget.10315. [Epub ahead of print]
35. Li J, D’Angiolella V, Seeley ES, Kim S, Kobayashi T, Fu W, Campos EI, Pagano M, Dynach B, USP33 regulates centrosome biogenesis via deubiquitination of the centriolar protein CP110. Nature. 2013;495:255–9.